Project Grant HT94252510351
Award Date
6/1/25
Completion Date
5/31/28
Dollars Obligated
$739K
Federal Agency
Defense Health Agency
Federal Grant Program
12.420
Assistance Type
Project Grant
Place of Performance
Los Angeles, CA 90024, USA
Similar Awards
The University of California, Los Angeles (UCLA) was awarded a $755,650 project grant from the Department of the Army Medical Command under the Military Medical Research and Development program (CFDA 12.420) to conduct research on "Validation of Biomarkers of Post-Traumatic Seizures in an Optimized Model of Traumatic Brain Injury". The award period runs from July 1, 2024 to June 30, 2026. As the prime grantee, UCLA will leverage its research capabilities, facilities, and faculty...
The Department of the Army Medical Command awarded a $1,180,437 Project Grant to the University of California, Los Angeles (UCLA) under the Military Medical Research and Development program (CFDA 12.420). The grant supports UCLA's research to evaluate circulating cell-free DNA as a biomarker for diagnosing and tracking the progression of amyotrophic lateral sclerosis (ALS). The award began on March 1, 2024 and is scheduled for completion by February 28, 2026. Through this Project Grant, UCLA...
The University of California, Los Angeles (UCLA), through its Office of Research Administration, was awarded a four-year $596,016 Project Grant from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420). The grant will support UCLA's research into "ENVIRONMENTAL AND GUT-BRAIN AXIS DETERMINANTS OF COGNITIVE OUTCOMES IN PD" from September 1, 2023 through August 31, 2027. As the prime awardee, UCLA will leverage its research expertise and...
This $1,181,251 Project Grant award from the Department of the Army Medical Command under the Military Medical Research and Development (CFDA 12.420) program supports research to develop neuronal exosome-based biomarkers for amyotrophic lateral sclerosis (ALS) diagnosis and disease progression. The prime awardee is the University of California, Los Angeles (UCLA), which will leverage its extensive medical research facilities, faculty expertise, and administrative capabilities to conduct this...
This federal Project Grant award, valued at $2,520,000.00, was issued by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420). The award supports advanced biomedical research initiatives focused on transforming healthcare for military service members and the broader public. The primary awardee, the University of California, Los Angeles (UCLA), will leverage its extensive facilities, diverse faculty expertise, and robust administrative capabilities...
This Project Grant award from the Department of the Army Medical Command under the Military Medical Research and Development (CFDA 12.420) program provides $1,557,266.00 to the University of California, Los Angeles (UCLA) to elucidate the molecular pathways by which proinflammatory microbes induce the development of interstitial cystitis. The award has a performance period from March 1, 2025 to February 28, 2029. As a leading research institution, UCLA will leverage its extensive facilities,...
The University of California, Los Angeles (UCLA), through its Office of Research Administration, has been awarded a $2,351,564.00 Project Grant from the Defense Health Agency under the CFDA Program 12.420 - Military Medical Research and Development. This four-year grant, with a period of performance from August 15, 2023 to August 14, 2027, will support research targeting the EGFR signaling network in glioblastoma. As the prime grantee, UCLA will leverage its research facilities, faculty...
The University of California, Los Angeles (UCLA), through its Office of Research Administration, has been awarded a $2,519,000 Project Grant from the Department of the Army Medical Command under the Military Medical Research and Development program (CFDA 12.420). The grant, awarded on April 1, 2024, will support research to investigate the role of inducible trypsins in mediating misfolding-dependent chronic pancreatitis, with a project completion date of March 31, 2028. As a prime grantee,...
The Defense Health Agency awarded the University of California, Los Angeles (UCLA) a $250,000 Project Grant titled "Probing Oligodendrocyte Lineage Cell Autocrine Signals to Treat Multiple Sclerosis" under the Military Medical Research and Development program (CFDA 12.420). This two-year grant, with a performance period from August 15, 2023 to August 14, 2025, supports UCLA's research to investigate treatment approaches for multiple sclerosis by studying autocrine signaling in...
This federal Project Grant award of $7,348,261.00 from the Department of the Army Medical Command under the Military Medical Research and Development (CFDA 12.420) program supports clinical evaluation of 4-aminopyridine in hereditary spinocerebellar ataxia. The grant was awarded to the University of California, Los Angeles (UCLA) for the project period from August 1, 2025 to July 31, 2027. The funding will enable UCLA, a leading public research university, to conduct advanced biomedical research...